. CEO Jeremy Weate tells Proactive the privately-held group has engaged , a group that invests in global, early-stage ventures in psychedelic medicine, as a strategic advisor for financing, and business plan development.

Weate says while the group anticipates completing a clinical trial application to submit to Health Canada using Ibogaine to treat opioid addiction, Universal Ibogaine will look to list its shares on the TSX-V in 1Q of 2021.